RNS Number: 7952P
DeepMatter Group PLC
21 Octoberr 2021


DeepMatter TO TRIAL ITS DIGITALGLASSWARE® platform with Aurigene Pharmaceutical Services

DeepMatter Group Plc (AIM: DMTR, “Deepmatter”, the “Group”), the international digital chemistry data company, has signed a trials agreement with Aurigene Pharmaceutical Services Limited (“Aurigene Pharmaceutical Services”), based in Hyderabad, India, to supply its DigitalGlassware® platform.

Aurigene Pharmaceutical Services is a fully integrated Contract Research, Development and Manufacturing Organization (CRO/CDMO) providing a wide range of services for small and large molecule.

DeepMatter will provide its DigitalGlassware® platform to Aurigene Pharmaceutical Services to help screen, develop and scale up chemistry procedures and to accelerate custom drug discovery and development projects.

Aurigene Pharmaceutical Services seeks to evaluate the technology to find efficiency and productivity gains through deeper data insights via collated aggregated data streams to better understand difficult synthetic routes and to foster active data sharing capabilities. The technology will help scan every reaction parameter and accelerate failed reaction diagnostics. Through this project Aurigene Pharmaceutical Services reinforces its focus to provide faster and efficient chemistry services to its customers and thus accelerating the drug discovery and development process.

DigitalGlassware® comprises a cloud-based software platform allowing scientists to easily bring together digitised synthesis protocols (recipes) and contextualised time-course sensor streams from a range of analytical instrumentation, in real-time (see note to editors below). 

Mark Warne, CEO of DeepMatter Group, commented:

"This paid for trials agreement is another positive step in our strategy to provide our DigitalGlassware® platform to the major global Contract Research Organisations (CRO’s) where the ability to reproduce is paramount in order to accelerate the discovery of new drugs."

Ravi Venkataraman,CEO of Aurigene Pharmaceutical Services commented:

“Aurigene Pharmaceutical Services is committed to leveraging cutting edge technologies to accelerate drug discovery and development, and providing differentiated services to our clients to bring new medicines to market. Digital transformation leveraging Artificial Intelligence (AI)/Machine Learning (ML) tools is a key focus area and our collaboration with DeepMatter is one step towards faster patient centric innovation”

 For more information, please contact:

DeepMatter Group plc

Mark Warne, Chief Executive Officer

T: 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker)

Bobbie Hilliam

T: 020 7523 8000

Meare Consulting

Adrian Duffield

T: 07990 858548


About DeepMatter Group plc

DeepMatter is building a unique, fully integrated digital chemistry cloud platform of chemical reaction data for scientists, who are working on early-stage chemical discovery & development.

DeepMatter is integrating technology with chemistry to enable scientists, principally in the commercial sector, to easily perform and optimise chemistry.  It is building, structuring and analysing chemical reaction databases and using this substantial data for real-time innovation and productivity gains in the chemical industry - particularly pharmaceutical companies engaged in pre-clinical drug discovery & development.  This data is also now enabling Artificial Intelligence (AI) driven chemical automation.

Times-course sensor data being the measuring of the effects of chemical reactions over the course of time, providing faster actionable insights that result in scientific breakthroughs.

Visit: and follow @deepmattergroup

About Aurigene Pharmaceutical Services Limited

Aurigene Pharmaceutical Services is a leading contract research, development and manufacturing organization (CDMO). Built on the legacy of accelerating innovation and backed by a vast CDMO pharma services experience in drug discovery, development and manufacturing our mission is to relentlessly work for the success of our clients and to build long-term relationships through a holistic approach to accelerate the journey of a molecule from the laboratory to market. By providing access to our resources, knowledge and experience, we create success for our clients and ultimately patients. As a CDMO pharma company we offer integrated and standalone services for discovery chemistry, discovery biology, development and manufacturing services for clinical phase I-III programs, regulatory submission batches and commercial manufacturing. A differentiating factor as a pharmaceutical contract manufacturing organization is the integrated API and formulations service that spans from key starting material, advanced intermediates, APIs to finished products such as oral solids, sterile products, nasal solutions etc. Our development and pharmaceutical API manufacturing services in India are complemented by cGMP commercial manufacturing facilities in the UK, Mexico, USA and India.

Aurigene is an independently managed wholly-owned subsidiary of Dr. Reddy’s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY).

For more information, log on to: or Email:

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



More news...